Sugi Predict

Sugi Predict / Compounds / SCHEMBL1601708

SCHEMBL1601708

SCHEMBL1601708

CC(C)(C)[Si](C)(C)Oc1ccc(CBr)cc1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PREP P48147 4/20 0.46
▸ CA12 O43570 4/20 0.42
▸ CA1 P00915 4/20 0.42
▸ CA9 Q16790 4/20 0.42
▸ TRPA1 O75762 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ DRD2 P14416 1/20 0.34
▸ ELANE P08246 1/20 0.32
▸ IDO1 P14902 2/20 0.31
▸ AGXT P21549 2/20 0.31
▸ CASP3 P42574 1/20 0.31
▸ CASP7 P55210 1/20 0.31
▸ PPARG P37231 1/20 0.30
▸ PPARA Q07869 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7012599 0.87 PREP (0.43) PREPCA12CA1CA9ALDH1A1
SCHEMBL6763899 0.85 PREP (0.53) PREPCA12CA1CA9ALDH1A1
SCHEMBL3843622 0.85 PREP (0.44) PREPCA12CA1CA9PPARA
SCHEMBL12426281 0.84 PREP (0.46) PREPCA12CA1CA9ALDH1A1
SCHEMBL318210 0.82 PPARA (0.47) PREPCA12CA1CA9TSHR
SCHEMBL6760799 0.82 PREP (0.45) PREPCA12CA1CA9DRD2
SCHEMBL11957424 0.82 PREP (0.45) PREPCA12CA1CA9
SCHEMBL14384880 0.82 PREP (0.45) PREPCA12CA1CA9DRD2
SCHEMBL4676713 0.82 IDO1 (0.50) PREPCA12CA1CA9ALDH1A1
SCHEMBL2087006 0.82 PREP (0.45) PREPCA12CA1CA9DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 — — US disclosed
EP-4626548-A1 NON PEPTIDERGIC AGONISTS OF OXYTOCIN RECEPTOR Université de Strasbourg (FR) 2025-10-08 — — EP disclosed
US-20240309020-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2024-09-19 — — US disclosed
WO-2024115667-A1 NON PEPTIDERGIC AGONISTS OF OXYTOCIN RECEPTOR UNIVERSITE DE STRASBOURG (FR) 2024-06-06 — — WO disclosed
US-11964989-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2024-04-23 — — US disclosed
US-20230279025-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-09-07 — — US disclosed
US-20230077225-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. 2023-03-09 — — US disclosed
US-11453683-B1 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2022-09-27 — — US disclosed
EP-4021444-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2022-07-06 — — EP disclosed
WO-2022098544-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2022-05-12 — — WO disclosed
WO-2007109334-A2 SIP RECEPTOR MODULATING COMPOUNDS AND USE THEREOF EPIX DELAWARE, INC. (US) 2007-09-27 — — WO disclosed
US-20070083034-A1 Novel dendritic polymers having monophosphonic terminations, method for preparing them, and their use RHODIA UK LTD. (GB) 2007-04-12 — — US disclosed
WO-2006074799-A2 5-PYRROLIDINYLSULFONYL ISATIN DERIVATIVES Universitätsklinikum Münster (DE) 2006-07-20 — — WO disclosed
WO-2006074799-A2 5-PYRROLIDINYLSULFONYL ISATIN DERIVATIVES Universitätsklinikum Münster (DE) 2006-07-20 — — WO disclosed
US-6117845-A C-linked analogs of N-(4-hydroxyphenyl) retinamide OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2000-09-12 — — US disclosed
EP-1020434-A1 3-AMIDINOANILINE DERIVATIVES, ACTIVATED BLOOD COAGULATION FACTOR X INHIBITORS, AND INTERMEDIATES FOR PRODUCING BOTH Kissei Pharmaceutical Co., Ltd. (JP) 2000-07-19 — — EP disclosed
US-5968951-A Benzenesulfonamide derivatives as bradykinin antagonists FOURNIER INDUSTRIE ET SANTE (FR) 1999-10-19 — — US disclosed
US-5246944-A Hypotensive and anxiolytic agents; antidepressants MERCK & CO., INC. (US) 1993-09-21 — — US disclosed
EP-0550924-A1 2-Pyrrolidinone derivatives as HIV protease inhibitors MERCK & CO. INC. (US) 1993-07-14 — — EP disclosed
EP-0527534-A1 Quinoline and azaquinoline angiotensin II antagonists MERCK & CO. INC. (US) 1993-02-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279025-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS PREP 2300/4885CA12 3764/4885CA1 3274/4885
US-20230077225-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS PREP 2371/4885CA12 3750/4885CA1 3229/4885
US-12630566-B2 KRas G12D inhibitors KRAS, NRAS, HRAS PREP 3223/4885CA12 3093/4885CA1 2449/4885
US-11964989-B2 KRas G12D inhibitors KRAS, NRAS, HRAS PREP 2231/4885CA12 3268/4885CA1 2753/4885
US-11453683-B1 KRas G12D inhibitors KRAS, NRAS, HRAS PREP 2146/4885CA12 3235/4885CA1 2721/4885
US-20240309020-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS PREP 2371/4885CA12 3750/4885CA1 3229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.